NuvOx Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	1.04	0.98	0.51
Revenue Growth (YoY)	-	91.41%	-
Gross Profit	1.04	0.98	0.51
Selling, General & Admin	-	1.23	1.27
Research & Development	-	4.85	4.07
Operating Expenses	-	6.08	5.33
Operating Income	-4.46	-5.1	-4.82
Interest Expense (Income)	0.01	0	-0.08
Other Expense (Income)	6.72	11.49	1.9
Pretax Income	-11.81	-17.21	-7.27
Net Income	-11.19	-16.59	-6.64
Preferred Dividends	0.62	0.62	0.62
Net Income Common	-11.81	-17.21	-7.27
Free Cash Flow	-1.78	-2.07	-3.74
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-430.53%	-520.71%	-941.02%
Profit Margin	-1140.97%	-1756.53%	-1419.53%
Free Cash Flow Margin	-171.88%	-211.33%	-730.86%
EBITDA	-11.68	-17.09	-7.24
EBITDA Margin	-1128.50%	-1744.29%	-1413.28%
Depreciation & Amortization	0.12	0.12	0.11
EBIT	-11.8	-17.21	-7.34
EBIT Margin	-1139.71%	-1756.43%	-1434.38%